Osteosarcoma: improved survival with anticoagulation and amputation.

A study of warfarin anticoagulation as an adjunct to amputation of osteosarcomas was undertaken after finding dramatic results in experimental systems. Anticoagulation was started 7 days preoperatively, continued during the operation, and for up to six months postoperatively. Three of 21 (14%) non-anticoagulated control patients are alive at 5-11 years. Five of 9 (56%) of the anticoagulated patients remain alive 5-8 years. The presumed mechanism of increased survival is an inhibition of fibrin deposition around circulating tumor cells, thereby preventing their adherence to capillary endothelium to initiate metastasis formation.
AuthorsH C Hoover Jr, A S Ketcham, R C Millar, H R Gralnick
JournalCancer (Cancer) Vol. 41 Issue 6 Pg. 2475-80 (Jun 1978) ISSN: 0008-543X [Print] UNITED STATES
PMID274994 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Warfarin
  • Adolescent
  • Adult
  • Amputation
  • Bone Neoplasms (blood, therapy)
  • Female
  • Hemorrhage (chemically induced)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis (prevention & control)
  • Neoplastic Cells, Circulating
  • Osteosarcoma (blood, therapy)
  • Prothrombin Time
  • Remission, Spontaneous
  • Time Factors
  • Warfarin (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: